OPNT News and Press, Opiant Pharmaceuticals Inc. From 02/08/21

Opiant Pharma (OPNT) announced the dosing of the first patient in a confirmatory pharmacokinetic ((PK)) study for OPNT003, nasal nalmefene, for the treatment of opioid overdose, with study results expected by June 2021.The open label, randomized, crossover study will enroll 68 healthy vo...

SANTA MONICA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced the dosing of the first patient in a confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for the treatment of o...

Prevail Therapeutics (PRVL) +84% on being acquired by Lilly for ~$1.04B.OncoCyte Corporation (OCX) +63% after company enters agreement with Burning Rock Biotech.Anavex Life Sciences (AVXL) +40% as it's blarcamesine successful in mid-stage rett syndrome study.Mid-Con Energy Part...

Opiant Pharmaceuticals (OPNT) has announced an additional commitment of up to $3.5M from the Biomedical Advanced Research and Development Authority (BARDA), to accelerate the development of OPNT003, nasal nalmefene, for opioid overdose.The contract modification increases the total p...

SANTA MONICA, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced Research and Development Authority (“BARDA”),...

Opiant Pharmaceuticals (OPNT) -1.44% AH, entered into a $50M convertible note purchase and security agreement with a syndicate of Pontifax Medison Finance, a healthcare-dedicated venture and debt fund, and Kreos Capital, Europe's leading growth debt firm.Proceeds to be used for fund...

SANTA MONICA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it has entered into a $50 million convertibl...

SANTA MONICA, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today the appointment of Craig A. Collard, a seasoned b...

Gainers: Medigus (MDGS) +30%, Aptevo Therapeutics (APVO) +29%, Corcept Therapeutics (CORT) +23%, Opiant Pharmaceuticals (OPNT) +15%, Aquestive Therapeutics (AQST) +11%.Losers: MeiraGTx Holdings (MGTX) -11%, Kintara Therapeutics (KTRA) -10%,&#x...

Opiant Pharmaceuticals, Inc. (OPNT) Q3 2020 Earnings Conference Call November 12, 2020 4:30 PM ET Company Participants Ben Atkins - VP, Communications & IR Roger Crystal - President, Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brandon Folke...